Boston Biomedical, Inc. - Product Pipeline Review - 2015

Boston Biomedical, Inc. - Product Pipeline Review - 2015 is a new market research publication announced by Reportstack. This report provides an overview of the Boston Biomedical, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Boston Biomedical, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team experts. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

To access full report with TOC, please visit Boston Biomedical, Inc. - Product Pipeline Review - 2015.
Scope

- The report provides brief overview of Boston Biomedical, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Boston Biomedical, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Boston Biomedical, Inc.’s pipeline products

Reasons to buy

- Evaluate Boston Biomedical, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Boston Biomedical, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Boston Biomedical, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Boston Biomedical, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Boston Biomedical, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Boston Biomedical, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Contact:

Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

CoLucid Pharmaceuticals, Inc. - Product Pipeline Review - 2015

CoLucid Pharmaceuticals, Inc. - Product Pipeline Review - 2015 is a new market research publication announced by Reportstack. This report provides an overview of the CoLucid Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CoLucid Pharmaceuticals, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team experts. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report with TOC available @ CoLucid Pharmaceuticals, Inc. - Product Pipeline Review - 2015.

Scope

- The report provides brief overview of CoLucid Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of CoLucid Pharmaceuticals, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the CoLucid Pharmaceuticals, Inc.’s pipeline products

Reasons to buy

- Evaluate CoLucid Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of CoLucid Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the CoLucid Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of CoLucid Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of CoLucid Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of CoLucid Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Contact:

Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Antares Pharma, Inc. - Product Pipeline Review - 2015

Antares Pharma, Inc. - Product Pipeline Review - 2015 is a new market research publication announced by Reportstack. This report provides an overview of the Antares Pharma, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Antares Pharma, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team experts. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

To access full report with TOC, please visit  Antares Pharma, Inc. - Product Pipeline Review - 2015.

Scope

- The report provides brief overview of Antares Pharma, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Antares Pharma, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Antares Pharma, Inc.’s pipeline products

Reasons to buy

- Evaluate Antares Pharma, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Antares Pharma, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Antares Pharma, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Antares Pharma, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Antares Pharma, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Antares Pharma, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Contact:

Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

TG Therapeutics, Inc. - Product Pipeline Review - 2015

TG Therapeutics, Inc. - Product Pipeline Review - 2015 is a new market research publication announced by Reportstack. This report provides an overview of the TG Therapeutics, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of TG Therapeutics, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

To access full report with TOC, please visit TG Therapeutics, Inc. - Product Pipeline Review - 2015.

Scope

- The report provides brief overview of TG Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of TG Therapeutics, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the TG Therapeutics, Inc.’s pipeline products

Reasons to buy

- Evaluate TG Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of TG Therapeutics, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the TG Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of TG Therapeutics, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of TG Therapeutics, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of TG Therapeutics, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Contact:

Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Halozyme Therapeutics, Inc. - Product Pipeline Review - 2015

Halozyme Therapeutics, Inc. - Product Pipeline Review - 2015 is a new market research publication announced by Reportstack. This report provides an overview of the Halozyme Therapeutics, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Halozyme Therapeutics, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team experts. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report available @ Halozyme Therapeutics, Inc. - Product Pipeline Review - 2015.

Scope

- The report provides brief overview of Halozyme Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Halozyme Therapeutics, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Halozyme Therapeutics, Inc.’s pipeline products

Reasons to buy

- Evaluate Halozyme Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Halozyme Therapeutics, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Halozyme Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Halozyme Therapeutics, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Halozyme Therapeutics, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Halozyme Therapeutics, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Contact:

Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Curis, Inc. - Product Pipeline Review - 2015

Curis, Inc. - Product Pipeline Review - 2015 is a new market research publication announced by Reportstack. This report provides an overview of the Curis, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Curis, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team members. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

To access full report with TOC, please visit  Curis, Inc. - Product Pipeline Review - 2015.

Scope

- The report provides brief overview of Curis, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Curis, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Curis, Inc.’s pipeline products

Reasons to buy
- Evaluate Curis, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Curis, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Curis, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Curis, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Curis, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Curis, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Contact:

Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Ariad Pharmaceuticals, Inc. - Product Pipeline Review - 2015

Ariad Pharmaceuticals, Inc. - Product Pipeline Review - 2015 is a new market research publication announced by Reportstack. This report provides an overview of the Ariad Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Ariad Pharmaceuticals, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team experts. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

To access full report with TOC, please visit Ariad Pharmaceuticals, Inc. - Product Pipeline Review - 2015.

Scope

- The report provides brief overview of Ariad Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Ariad Pharmaceuticals, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Ariad Pharmaceuticals, Inc.’s pipeline products

Reasons to buy

- Evaluate Ariad Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Ariad Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Ariad Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Ariad Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Ariad Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Ariad Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Contact:

Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Faron Pharmaceuticals Oy - Product Pipeline Review - 2015

Faron Pharmaceuticals Oy - Product Pipeline Review - 2015 is a new market research publication announced by Reportstack. This report provides an overview of the Faron Pharmaceuticals Oy’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Faron Pharmaceuticals Oy’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team experts. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report available @ Faron Pharmaceuticals Oy - Product Pipeline Review - 2015.

Scope

- The report provides brief overview of Faron Pharmaceuticals Oy including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Faron Pharmaceuticals Oy’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Faron Pharmaceuticals Oy’s pipeline products

Reasons to buy

- Evaluate Faron Pharmaceuticals Oy’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Faron Pharmaceuticals Oy in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Faron Pharmaceuticals Oy’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Faron Pharmaceuticals Oy and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Faron Pharmaceuticals Oy
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Faron Pharmaceuticals Oy and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Contact:

Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

AvidBiotics Corp. - Product Pipeline Review - 2015

AvidBiotics Corp. - Product Pipeline Review - 2015 is a new market research publication announced by Reportstack. This report provides an overview of the AvidBiotics Corp.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of AvidBiotics Corp.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team experts. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

To access full report with TOC, please visit AvidBiotics Corp. - Product Pipeline Review - 2015.

Scope

- The report provides brief overview of AvidBiotics Corp. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of AvidBiotics Corp.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the AvidBiotics Corp.’s pipeline products

Reasons to buy

- Evaluate AvidBiotics Corp.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of AvidBiotics Corp. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the AvidBiotics Corp.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of AvidBiotics Corp. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of AvidBiotics Corp.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of AvidBiotics Corp. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Contact:

Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Vybion, Inc. - Product Pipeline Review - 2015

Vybion, Inc. - Product Pipeline Review - 2015 is a new market research publication announced by Reportstack. This report provides an overview of the Vybion, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Vybion, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

To view the table of contents and know more details, please visit  Vybion, Inc. - Product Pipeline Review - 2015.

Scope

- The report provides brief overview of Vybion, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Vybion, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Vybion, Inc.’s pipeline products

Reasons to buy

- Evaluate Vybion, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Vybion, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Vybion, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Vybion, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Vybion, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Vybion, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Contact:

Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Galenea Corp. - Product Pipeline Review - 2015

Galenea Corp. - Product Pipeline Review - 2015 is a new market research publication announced by Reportstack. This report provides an overview of the Galenea Corp.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Galenea Corp.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team experts. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

To access full report with TOC, please visit Galenea Corp. - Product Pipeline Review - 2015.

Scope

- The report provides brief overview of Galenea Corp. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Galenea Corp.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Galenea Corp.’s pipeline products

Reasons to buy

- Evaluate Galenea Corp.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Galenea Corp. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Galenea Corp.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Galenea Corp. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Galenea Corp.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Galenea Corp. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Contact:

Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Shigella Infections (Shigellosis) Global Clinical Trials Review, H1, 2015

Shigella Infections (Shigellosis) Global Clinical Trials Review, H1, 2015 is a new market research publication announced by Reportstack. This report provides data on the Shigella Infections (Shigellosis) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Shigella Infections (Shigellosis). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Shigella Infections (Shigellosis). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

To view the table of contents and know more details please visit Shigella Infections (Shigellosis) Global Clinical Trials Review, H1, 2015

Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies


Companies Mentioned

GlaxoSmithKline plc Novartis AG Icddr

Contact:

Debora White
Manager - Marketing 
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research

Celiac Disease Global Clinical Trials Review, H1, 2015

Celiac Disease Global Clinical Trials Review, H1, 2015 is a new market research publication announced by Reportstack. This report provides data on the Celiac Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Celiac Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Celiac Disease. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

Complete report available @ Celiac Disease Global Clinical Trials Review, H1, 2015

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies


Companies Mentioned

Alba Therapeutics Corporation ImmusanT, Inc. Alvine Pharmaceuticals, Inc. Royal DSM N.V. Parexel International Corporation BioLineRx, Ltd. Meda AB InVentiv Group Holdings, Inc. ChemoCentryx, Inc. Calypso Biotech SA

Contact:

Debora White
Manager - Marketing 
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research

Diabetic Gastroparesis Global Clinical Trials Review, H1, 2015

Diabetic Gastroparesis Global Clinical Trials Review, H1, 2015 is a new market research publication announced by Reportstack. This report provides data on the Diabetic Gastroparesis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diabetic Gastroparesis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Diabetic Gastroparesis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

Complete report available @ Diabetic Gastroparesis Global Clinical Trials Review, H1, 2015

Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies


Companies Mentioned

Evoke Pharma, Inc. Rhythm Pharmaceuticals Ocera Therapeutics, Inc. Ironwood Pharmaceuticals, Inc. Theravance, Inc. Targacept, Inc. GlaxoSmithKline plc Alfa Wassermann S.p.A Chong Kun Dang Pharmaceutical Corp Axis Clinical Trials

Contact:

Debora White
Manager - Marketing 
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research

Gestational Diabetes Global Clinical Trials Review, H1, 2015

Gestational Diabetes Global Clinical Trials Review, H1, 2015 is a new market research publication announced by Reportstack. This report provides data on the Gestational Diabetes clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Gestational Diabetes. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Gestational Diabetes. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

To view the table of contents and know more details please visit Gestational Diabetes Global Clinical Trials Review, H1, 2015

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies


Companies Mentioned

Novo A/S Galenica Ltd. F. Hoffmann-La Roche Ltd. Eli Lilly and Company E. Merck KG A. Menarini Industrie Farmaceutiche Riunite Srl

Contact:

Debora White
Manager - Marketing 
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research

Liver Fibrosis Global Clinical Trials Review, H1, 2015

Liver Fibrosis Global Clinical Trials Review, H1, 2015 is a new market research publication announced by Reportstack. This report provides data on the Liver Fibrosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Liver Fibrosis . It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Liver Fibrosis . This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

To access full report with TOC, please visit Liver Fibrosis Global Clinical Trials Review, H1, 2015
Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies


Companies Mentioned

Merck & Co., Inc. F. Hoffmann-La Roche Ltd. Pfizer Inc. Gilead Sciences, Inc. Nitto Denko Corporation Galectin Therapeutics, Inc. C. H. Boehringer Sohn AG & Co. KG FibroGen, Inc. Conatus Pharmaceuticals Inc. Astellas Pharma Inc.

Contact:

Debora White
Manager - Marketing 
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research